409P - Prognostic value of 18F-FDG PET parameters in Patients with Locally Advanced Non–Small-Cell Lung Cancer treated with Induction Chemotherapy (409P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Locally Advanced
Imaging, Diagnosis and Staging
Lung and other Thoracic Tumours
Presenter Hee Yeon Lee
Citation Annals of Oncology (2017) 28 (suppl_10): x122-x123. 10.1093/annonc/mdx670
Authors H.Y. Lee1, W.H. Choi2, J. Kim3, I.R. Yoo4, J.K. Park5, S.W. Sung5, Y.S. Kim6, J.H. Kang7
  • 1Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital, 21431 - Incheon/KR
  • 2Radiology, The Catholic University of Korea St. Vincent's Hospital, 16247 - Suwon/KR
  • 3Bioscience, The Catholic University of Korea, 06591 - Seoul/KR
  • 4Nuclear Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 5Thoracic And Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 6Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 137-701 - Seoul/KR
  • 7Internal Medicine, College of Medicine, The Catholic University of Korea, 06591 - Seoul/KR

Abstract

Background

This study aimed to investigate prognostic role of metabolic parameters using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG PET) in patients with locally advanced NSCLC treated with docetaxel-platinum induction chemotherapy.

Methods

Medical records of 31 patients with pre- and post-IC 18FDG PET were reviewed. Using 18FDG PET, metabolic parameters were assessed including metabolic tumor response according to PERCIST 1.0, adjusted peak standardized uptake values using lean body mass at baseline (pre-SULpeak) and after 2 cycles of IC (post-SULpeak), and percentage change of pre- and post-SULpeak (ΔSULpeak).

Results

Response rate was 71% and metabolic response rate was 83.9%. Median pre-SULpeak, post-SULpeak, and ΔSULpeak was 6.1, 2.0 and 63%, respectively. After IC, 19 patients (61.3%) underwent surgery and R0 resection was achieved in 17 patients. 7 patients (22.6%) received concurrent chemoradiation (CCRT), 2 patients (6.5%) received radiotherapy alone, best supportive care was done in 2 patients (6.5%), and 1 patient was lost to follow-up. Median relapse free survival (RFS) was 8.9 months (95% CI, 4.5–12.1 and median overall survival (OS) was 24.1 months (95% CI 17.1–34.1). Kaplan Meier survival analysis showed longer median RFS and OS in patients with post-SULpeak 60% (RFS, 20.6 vs. 6.9 months; log rank p 

Conclusions

Our findings have shown that post-SULpeak 60% for OS in patients with locally advanced NSCLC receiving docetaxel platinum IC. And post-SULpeak

Clinical trial identification

Legal entity responsible for the study

Hee Yeon Lee

Funding

None

Disclosure

All authors have declared no conflicts of interest.